EBMT-EHA CAR-T 2019 | The future of CAR T-cell therapy for AML

Elizabeth Budde

Using CAR T-cell therapy earlier in acute myeloid leukemia progression may benefit patients. Elizabeth Budde, MD, PhD City of Hope National Medical Center, Duarte, CA, speaks at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

Transcript (edited for clarity):

We would like to be able to move this CAR T-cell treatment to an earlier stage. For example, once we know enough about the efficacy, we can consider moving this to patients. For example, after initial failed induction treatment, after the first or second line of treatment, we can also consider maybe use this CAR T-cell therapy in a maintenance or consolidation strategy in patients with minimal residual disease. So patient will benefit much earlier on rather than waiting for them to have multiple prior lines of therapies and really not in a good medical condition to really go through CAR T-cell therapies, so making it available for more patients.

Share this video